Effect of a single glass of grapefruit juice on the apparent oral bioavailability of the dihydropyridine calcium channel antagonist, azelnidipine, in healthy Japanese volunteers

Japanese Journal of Clinical Pharmacology and Therapeutics

Volumn 37, Issue 3, 2006, Pages 127-133

  Hirashima, Hayato ^a   Uchida, Naoki ^a   Fukazawa, Ichiro ^a   Ishigaki, Seiichiro ^a   Uchida, Eiji ^a   Yasuhara, Hajime ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Azelnidipine; CYP3A4; Drug interaction; Grapefruit juice

Indexed keywords

AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 CYP3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; FELODIPINE; NIFEDIPINE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; FLUSHING; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HUMAN EXPERIMENT; JAPAN; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; SIDE EFFECT;

EID: 33745669902     PISSN: 03881601     EISSN: None     Source Type: Journal    
DOI: 10.3999/jscpt.37.3_127     Document Type: Article

References (33)

1. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
2. Toyo-oka T. Therapeutic evolution brought by a new generation (3-rd generation type-b) calcium channel antagonist, Azelnidipine. Prog Med 2006; 23: 1145-50 (in Japanese).
3. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-8 (in Japanese).
4. Kazui M, Ikeda T, Yamazoe Y. Drug-interaction of Ca-channel blockers. Prog Med 2004; 24: 2653-8 (in Japanese).
5. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 1998; 18: 251-72.
6. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9.
7. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10.
8. Fuhr U, Muller-Peltzer H, Kern R, Lopez-Rojas P, Junemann M, Harder S, Staib AH. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 2002; 58: 45-53. Epub 2002 Mar 15.
9. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-8.
10. Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matthey K, Balogh A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996; 53: 41-7.
11. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbug S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-8.
12. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9.
13. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effect of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004; 57: 448-55.
14. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-53.
15. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effect of grapefruit juice ingestion on pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-45.
16. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54: 589-94.
17. Lilja JJ, Kivisto KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000; 56: 411-5.
18. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998; 23: 55-9.
19. Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-905, a new calcium antagonist- II: a single dose study on healthy volunteers: influence of food intake Rinsho Iyaku 2000; 16: 179-90. (in Japanese).
20. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grape fruit juice, furocoumarin dimmers as components of drug interaction. Pharmacogenetics 1997; 7: 391-6.
21. Bailey DG, Dresser GK, Bend JR. Bergamotin, lime juice and red wine as inhibitors of cytochrome P450 3A4 activity, comparison with grapefruit juice. Clin Pharmacol Ther 2003; 73: 529-37.
22. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, Sawada Y. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000; 49: 49-58.
23. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189-93.
24. Dorne JLCM, Walton K, Renwick AG. Human variability in CYF3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 2003; 41: 201-24.
25. Salttel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988; 36: 387-428.
26. Waller DG, Renwick AG, Gruchy BS, George CF. The first pass metabolism of nifedipine in man. Br J Clin Parmacol 1984; 18: 951-4.
27. Vincent J, Harris S, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol 2000; 50: 455-63.
28. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-34.
29. Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, Ronn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther 1985; 38: 205-11.
30. Sada T, Mizuno M, Miyama C. Pharmacological properties of azelnidipine, a long-acting calcium channel blocker with high affinity for vascular tissues: calcium-channel blocking actions in receptor binding and isolated blood vessel studies. Jpn Pharmacol Ther 2002; 30: 703-9 (in Japanese).
31. Wellington K, Scott LJ. Azelnidipine. Drugs 2003; 63: 2613-21.
32. Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-905, a new calcium antagonist- I: a single dose study on healthy volunteers. Rinsho Iyaku 2000; 16: 163-77.
33. Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-9D5, a new calcium antagionist-III: a multiple dose study on healthy volunteers. Rinsho Iyaku 2000; 16: 191-205 (in Japanese).